AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01701622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks.
Study NCT03775837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Ginseng C.A. Mey Extract group
Description: This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
Study NCT03775837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes placebo for 8 weeks
Study NCT03335540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03335540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified day
Study NCT03335540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Specified dose on specified day
Study NCT03335540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day
Study NCT03335540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor
Description: Specified dose on specified day
Study NCT03335540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Specified dose on specified day
Study NCT02867397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Teysuno (S1) in combination with epirubicin and oxaliplatin
Study NCT04217369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabits Predictions
Description: Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
Study NCT01139034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-designed surface functional electrical stimulator
Description: Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White Bread
Description: About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added 7.32g Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added 15.58g Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
Study NCT00260039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Gardasil
Description: 0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
Study NCT00260039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 1
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
Study NCT00260039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 2
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
Study NCT00260039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 3
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
Study NCT01292720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
Study NCT01292720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in matching volumes
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg for s.c. (under the skin) injection.
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1.5-2.0 g tablets
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice milk
Description: Rice milk containing 50g of available carbohydrates
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 7.32g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 15.58g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
Study NCT00728065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 24g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
Study NCT01271140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
Study NCT02195492 — intervention group
Intervention type: DRUG
Intervention: Synvisc®
Study NCT00914381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy
Study NCT02718859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
Study NCT02718859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation (IRE )
Description: The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
Study NCT02718859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: irreversible electroporation (IRE )
Description: The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
Study NCT02906254 — intervention group
Intervention type: OTHER
Intervention: ECIL-4 guidelines group
Description: Antibiotics were stopped when patients had been afebrile for more than 48 hours
Study NCT02906254 — intervention group
Intervention type: OTHER
Intervention: Short-course antibiotic therapy
Description: Antibiotics were stopped on day 5 in febrile or afebrile patients
Study NCT03172689 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CardioQ
Description: comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1.5-2.0 g tablets
Study NCT02673229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Santyl
Description: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
Study NCT02673229 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bacitracin
Description: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
Study NCT01710930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of predictive factors
Description: Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9).
Study NCT01147926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Prucalopride tablet orally once daily.
Study NCT01147926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
Study NCT01444807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400 mg bid
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 4 mg tablets
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets
Study NCT01096914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous radiofrequency ablation
Description: Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study NCT01096914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous laser ablation
Description: Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study NCT03630055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG Oral Tablet [Xarelto]
Description: Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
Study NCT05120063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPS monoblock stem, Symbios
Description: hip prosthesis
Study NCT05120063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quadra-H, Medacta
Description: hip prosthesis
Study NCT05120063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D planning of THR
Description: primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
Study NCT05120063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D planning of THR
Description: primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
Study NCT02842554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EPT
Study NCT02842554 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug Placebo Administration
Study NCT02842554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: C
Description: No Intervention
Study NCT02976155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A standard enteral nutrition protocol
Description: Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
Study NCT00781365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitors and pharmacy management
Description: Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
Study NCT01284881 — intervention group
Intervention type: DEVICE
Intervention: MRA
Description: daily wear overnight
Study NCT00363831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m² infusion day 1, repeat every 21 days
Study NCT01708031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological signals
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
Study NCT02857218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Undergo ferumoxytol-enhanced MRI
Study NCT02857218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo ferumoxytol-enhanced MRI
Study NCT01727258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Rinse
Description: Mouth rinse 12027-033 used twice daily for 28 days after brushing.
Study NCT01727258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Toothpaste
Description: Fluoride Toothpaste used daily for 28 days.
Study NCT01727258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste
Description: Fluoride Toothpaste used daily for 28 days.
Study NCT01727258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate Toothpaste
Description: Potassium Nitrate Toothpaste used daily for 28 days.
Study NCT05146557 — intervention group
Intervention type: OTHER
Intervention: Dental examination
Description: In this cross sectional observational study only Dental examination and a self response survey was applied.
Study NCT01960855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: ABT-494 capsule administered orally twice daily (BID).
Study NCT01960855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-494 capsule administered orally twice daily (BID).
Study NCT02524431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of trabecular meshwork tissue during surgery
Description: Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
Study NCT03079440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEMCAP
Description: Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
Study NCT02013544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02013544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone (DHEA)
Study NCT02932956 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GAP T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study NCT02932956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
Study NCT02932956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
Study NCT03339804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
Study NCT00355264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoptin
Description: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
Study NCT01157117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for omalizumab
Description: Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
Study NCT01157117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
Study NCT01157117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk powder
Description: Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
Study NCT01157117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milk powder
Description: Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
Study NCT02825121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Neuromuscular Blockade the Flexor Hallucis
Study NCT02825121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Neuromuscular Blockade adductor of the thumb.
Study NCT01075347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous serum
Description: with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
Study NCT01075347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-autologous serum
Description: without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
Study NCT03707457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT03707457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GITR Monoclonal Antibody MK-4166
Description: Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT03707457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 inhibitor INCB024360
Description: Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg for s.c. (under the skin) injection
Study NCT03707457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
Study NCT03432728 — intervention group
Intervention type: PROCEDURE
Intervention: Dental rehabilitation under general anesthesia
Description: Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia